The Journal of Pain
Volume 9, Issue 6 , Pages 506-521 , June 2008

A Randomized, Placebo-Controlled, Crossover Trial of Cannabis Cigarettes in Neuropathic Pain

  • Barth Wilsey

      Affiliations

    • VA Northern California Health Care System, Department of Anesthesiology and Pain Medicine, University of California, Davis Medical Center, Davis, California.
    • Corresponding Author InformationAddress reprint requests to Dr. Barth L. Wilsey, Pain Academic Office, UC Davis Medical Center, 3020 Ellison Ambulatory Care Center, 4860 Y Street, Sacramento, CA 95817.
    • ,
  • Thomas Marcotte

      Affiliations

    • Department of Psychiatry, University of California, San Diego, California.
    • ,
  • Alexander Tsodikov

      Affiliations

    • UC Davis/VANCHCS General Clinical Research Center and Department of Public Health Sciences, University of California, Davis Medical Center, Davis, California.
    • ,
  • Jeanna Millman

      Affiliations

    • Department of Anesthesiology and Pain Medicine, University of California, Davis Medical Center, Davis, California.
    • ,
  • Heather Bentley

      Affiliations

    • University of California Center for Medicinal Cannabis Research, University of California, San Diego, California.
    • ,
  • Ben Gouaux

      Affiliations

    • University of California Center for Medicinal Cannabis Research, University of California, San Diego, California.
    • ,
  • Scott Fishman

      Affiliations

    • Department of Anesthesiology and Pain Medicine, University of California, Davis Medical Center, Davis, California.

Received 25 June 2007 ,Revised 10 December 2007 ,Accepted 18 December 2007.

References 

  1. Ad Hoc Group of Experts, Report to the Director, National Institutes of Health: Workshop on the Medical Utility of Marijuana, February 19-20, 1997
  2. Abrams DI, Jay CA, Shade SB, Vizoso H, Reda H, Press S, et al. Cannabis in painful HIV-associated sensory neuropathy: A randomized placebo-controlled trial. Neurology. 2007;68:515–521
  3. Abrams DI, Vizoso HP, Shade SB, Jay C, Kelly ME, Benowitz NL. Vaporization as a smokeless cannabis delivery system: A pilot study. Clin Pharmacol Ther. 2007;82:572–578
  4. Azorlosa JL, Heishman SJ, Stitzer ML, Mahaffey JM. Marijuana smoking: Effect of varying delta 9-tetrahydrocannabinol content and number of puffs. J Pharmacol Exp Ther. 1992;261:114–122
  5. Barnes MP. Sativex: Clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain. Exp Opin Pharmacother. 2006;7:607–615
  6. Beglinger LJ, Gaydos B, Tangphao-Daniels O, Duff K, Kareken DA, Crawford J, et al. Practice effects and the use of alternate forms in serial neuropsychological testing. Arch Clin Neuropsychol. 2005;20:517–529
  7. Benedict RH, Schretlen D, Groninger L, Brandt J. Hopkins Verbal Learning Test-Revised: Normative data and analysis of inter-form and test-retest reliability. Clin Neuropsychol. 1998;12:43–55
  8. Benedict RH, Zgaljardic DJ. Practice effects during repeated administrations of memory tests with and without alternate forms. J Clin Exp Neuropsychol. 1998;20:339–352
  9. Berigan TR. Modafinil treatment of excessive sedation associated with divalproex sodium. Can J Psychiatry. 2004;49:72–73
  10. Berigan TR. Modafinil treatment of excessive daytime sedation and fatigue associated with topiramate. Prim Care Companion J Clin Psychiatry. 2002;4:249–250
  11. Berman JS, Symonds C, Birch R. Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: Results of a randomised controlled trial. Pain. 2004;112:299–306
  12. Black DR, Sang CN. Advances and limitations in the evaluation of analgesic combination therapy. Neurology. 2005;65:S3–S6
  13. Bostrom BA. Gonzales v Raich (In the Supreme Court of the United States). Issues Law Med. 2005;21:47–56
  14. Bruehl S, Harden RN, Galer BS, Saltz S, Bertram M, Backonja M, et al. External validation of IASP diagnostic criteria for Complex Regional Pain Syndrome and proposed research diagnostic criteria: International Association for the Study of Pain. Pain. 1999;81:147–154
  15. Campbell FA, Tramer MR, Carroll D, Reynolds DJ, Moore RA, McQuay HJ. Are cannabinoids an effective and safe treatment option in the management of pain? (A qualitative systematic review). BMJ. 2001;323:13–16
  16. Carey CL, Woods SP, Gonzalez R, Conover E, Marcotte TD, Grant I, et al. Predictive validity of global deficit scores in detecting neuropsychological impairment in HIV infection. J Clin Exp Neuropsychol. 2004;26:307–319
  17. Chait LD, Corwin RL, Johanson CE. A cumulative dosing procedure for administering marijuana smoke to humans. Pharmacol Biochem Behav. 1988;29:553–557
  18. Cichewicz DL. Synergistic interactions between cannabinoid and opioid analgesics. Life Sci. 2004;74:1317–1324
  19. Cichewicz DL, McCarthy EA. Antinociceptive synergy between delta(9)-tetrahydrocannabinol and opioids after oral administration. J Pharmacol Exp Ther. 2003;304:1010–1015
  20. Clark WC, Janal MN, Zeidenberg P, Nahas GG. Effects of moderate and high doses of marihuana on thermal pain: A sensory decision theory analysis. J Clin Pharmacol. 1981;21:299S–310S
  21. Collie A, Maruff P, Darby DG, McStephen M. The effects of practice on the cognitive test performance of neurologically normal individuals assessed at brief test-retest intervals. J Int Neuropsychol Soc. 2003;9:419–428
  22. Day R, Wodak A, Chesher G. Cannabis and suicide. Med J Aust. 1994;160:731
  23. Dellemijn P. Are opioids effective in relieving neuropathic pain?. Pain. 1999;80:453–462
  24. Di Forti M, Morrison PD, Butt A, Murray RM. Cannabis use and psychiatric and cognitive disorders: The chicken or the egg?. Curr Opin Psychiatry. 2007;20:228–234
  25. Dornbush RL, Kokkevi A. Acute effects of cannabis on cognitive, perceptual, and motor performance in chronic hashish users. Ann N Y Acad Sci. 1976;282:313–322
  26. Farrar JT, Young JP, LaMoreaux L, Werth JL, Poole RM. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain. 2001;94:149–158
  27. Galer BS, Bruehl S, Harden RN. IASP diagnostic criteria for complex regional pain syndrome: A preliminary empirical validation study: International Association for the Study of Pain. Clin J Pain. 1998;14:48–54
  28. Galer BS, Jensen MP. Development and preliminary validation of a pain measure specific to neuropathic pain: The Neuropathic Pain Scale. Neurology. 1997;48:332–338
  29. Gieringer D. Marijuana research: Waterpipe study. MAPS (Multidisciplinary Association for Psychedelic Studies) Bull. 1996;6:59–66
  30. Gieringer D, St. Laurent J, Goodrich S. Cannabis vaporizer combines efficient delivery of THC with effective suppression of pyrolytic compounds. J Cannabis Ther. 2004;4:
  31. Greenwald MK, Stitzer ML. Antinociceptive, subjective and behavioral effects of smoked marijuana in humans. Drug Alcohol Depend. 2000;59:261–275
  32. Hansson P, Lindblom U. Hyperalgesia assessed with quantitative sensory testing in patients with neurogenic pain. In:  Willis WDJ editors. Hyperalgesia and Allodynia. New York: Raven Press; 1992;p. 335–343
  33. Harden RN, Bruehl S, Galer BS, Saltz S, Bertram M, Backonja M, et al. Complex regional pain syndrome: Are the IASP diagnostic criteria valid and sufficiently comprehensive?. Pain. 1999;83:211–219
  34. Harder S, Rietbrock S. Concentration-effect relationship of delta-9-tetrahydrocannabiol and prediction of psychotropic effects after smoking marijuana. Int J Clin Pharmacol Ther. 1997;35:155–159
  35. Hart CL, van Gorp W, Haney M, Foltin RW, Fischman MW. Effects of acute smoked marijuana on complex cognitive performance. Neuropsychopharmacology. 2001;25:757–765
  36. Heaton R, Grant I, Matthews C. Comprehensive norms for an expanded Halstead-Reitan Battery: Demographic corrections, research findings, and clinical applications. Odessa, FL: Psychological Assessment Resources, Inc; 1991;
  37. Heaton R, Miller S, Taylor M, Grant I: Revised Comprehensive norms for an expanded Halstead-Reitan Battery: Demographically adjusted neuropsychological norms for African American and Caucasian adults, in Lutz F (ed): Psychological Assessment Resources, Inc., 2004
  38. In:  Heaton R,  Taylor M,  Manly J editor. Demographic effects and use of demographically corrected norms with the WAIS-III and WMS-III. San Diego, CA: Academic Press; 2004;
  39. Heaton RK, Marcotte TD. Clinical Neuropsychological Tests and Assessment Techniques. In:  Boller F,  Grafman J,  Rizzolatti G editor. Handbook of Neuropsychology. Amsterdam: Elsevier Science BV; 2000;
  40. Herkenham M, Lynn AB, Johnson MR, Melvin LS, de Costa BR, Rice KC. Characterization and localization of cannabinoid receptors in rat brain: A quantitative in vitro autoradiographic study. J Neurosci. 1991;11:563–583
  41. Herzberg U, Eliav E, Bennett GJ, Kopin IJ. The analgesic effects of R(+)-WIN 55,212-2 mesylate, a high affinity cannabinoid agonist, in a rat model of neuropathic pain. Neurosci Lett. 1997;221:157–160
  42. Hiller FC, Wilson FJ, Mazumder MK, Wilson JD, Bone RC. Concentration and particle size distribution in smoke from marijuana cigarettes with different delta 9-tetrahydrocannabinol content. Fundam Appl Toxicol. 1984;4:451–454
  43. Iezzi T, Archibald Y, Barnett P, Klinck A, Duckworth M. Neurocognitive performance and emotional status in chronic pain patients. J Behav Med. 1999;22:205–216
  44. Iezzi T, Duckworth MP, Vuong LN, Archibald YM, Klinck A. Predictors of neurocognitive performance in chronic pain patients. Int J Behav Med. 2004;11:56–61
  45. Johanek LM, Simone DA. Activation of peripheral cannabinoid receptors attenuates cutaneous hyperalgesia produced by a heat injury. Pain. 2004;109:432–442
  46. Kelly TH, Foltin RW, Fischman MW. Effects of smoked marijuana on heart rate, drug ratings and task performance by humans. Behav Pharmacol. 1993;4:167–178
  47. Klove H. Clinical neuropsychology. In:  Forster FE editors. The Medical Clinics of North America. New York, NY: Saunders; 1963;
  48. Lorber L. Gonzales v Raich: the US Supreme Court's consideration captured the public policy debate about the medical use of marijuana. Gend Med. 2005;2:124–130
  49. Makela EH, Miller K, Cutlip WD. Three case reports of modafinil use in treating sedation induced by antipsychotic medications. J Clin Psychiatry. 2003;64:485–486
  50. Malik R, Sangwan A, Saihgal R, Jindal DP, Piplani P. Towards better brain management: Nootropics. Curr Med Chem. 2007;14:123–131
  51. Matthias P, Tashkin DP, Marques-Magallanes JA, Wilkins JN, Simmons MS. Effects of varying marijuana potency on deposition of tar and delta9-THC in the lung during smoking. Pharmacol Biochem Behav. 1997;58:1145–1150
  52. McPartland JM, Pruitt PL. Medical marijuana and its use by the immunocompromised. Altern Ther Health Med. 1997;3:39–45
  53. Miller LL, McFarland D, Cornett TL, Brightwell D. Marijuana and memory impairment: Effect on free recall and recognition memory. Pharmacol Biochem Behav. 1977;7:99–103
  54. Moore TH, Zammit S, Lingford-Hughes A, Barnes TR, Jones PB, Burke M, et al. Cannabis use and risk of psychotic or affective mental health outcomes: A systematic review. Lancet. 2007;370:319–328
  55. Noyes R, Brunk SF, Avery DA, Canter AC. The analgesic properties of delta-9-tetrahydrocannabinol and codeine. Clin Pharmacol Ther. 1975;18:84–89
  56. Noyes R, Brunk SF, Baram DA, Canter A. Analgesic effect of delta-9-tetrahydrocannabinol. J Clin Pharmacol. 1975;15:139–143
  57. Okie S. Medical marijuana and the Supreme Court. N Engl J Med. 2005;353:648
  58. Pope HG, Gruber AJ, Yurgelun-Todd D. Residual neuropsychologic effects of cannabis. Curr Psychiatry Rep. 2001;3:507–512
  59. Price DD, Harkins SW, Baker C. Sensory-affective relationships among different types of clinical and experimental pain. Pain. 1987;28:297–307
  60. Price DD, Harkins SW, Rafii A, Price C. A simultaneous comparison of fentanyl's analgesic effects on experimental and clinical pain. Pain. 1986;24:197–203
  61. Price DD, Von der Gruen A, Miller J, Rafii A, Price C. A psychophysical analysis of morphine analgesia. Pain. 1985;22:261–269
  62. Rog DJ, Nurmikko TJ, Friede T, Young CA. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology. 2005;65:812–819
  63. Rowbotham MC. Mechanisms of neuropathic pain and their implications for the design of clinical trials. Neurology. 2005;65:S66–S73
  64. Russo E, Guy GW. A tale of two cannabinoids: The therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Med Hypotheses. 2006;66:234–246
  65. Schnelle M, Grotenhermen F, Reif M, Gorter RW. Results of a standardized survey on the medical use of cannabis products in the German-speaking area. Forsch Komplementarmed. 1999;6((Suppl)3):28–36
  66. Tsou K, Brown S, Sanudo-Pena MC, Mackie K, Walker JM. Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience. 1998;83:393–411
  67. Turner DC, Clark L, Dowson J, Robbins TW, Sahakian BJ. Modafinil improves cognition and response inhibition in adult attention-deficit/hyperactivity disorder. Biol Psychiatry. 2004;55:1031–1040
  68. Turner DC, Clark L, Pomarol-Clotet E, McKenna P, Robbins TW, Sahakian BJ. Modafinil improves cognition and attentional set shifting in patients with chronic schizophrenia. Neuropsychopharmacology. 2004;29:1363–1373
  69. Van Gorp WG, Lamb DG, Schmitt FA. Methodologic issues in neuropsychological research with HIV-spectrum disease. Arch Clin Neuropsychol. 1993;8:17–33
  70. Vaughan CW, Christie MJ. An analgesic role for cannabinoids. Med J Aust. 2000;173:270–272
  71. Walker JM, Hohmann AG. Cannabinoid mechanisms of pain suppression. Handb Exp Pharmacol. 2005;509–554
  72. Ware MA, Doyle CR, Woods R, Lynch ME, Clark AJ. Cannabis use for chronic non-cancer pain: Results of a prospective survey. Pain. 2003;102:211–216
  73. Ware MA, Gamsa A, Persson J, Fitzcharles MA. Cannabis for chronic pain: Case series and implications for clinicians. Pain Res Manag. 2002;7:95–99
  74. Webster L, Andrews M, Stoddard G. Modafinil treatment of opioid-induced sedation. Pain Med. 2003;4:135–140
  75. Wechsler D: Wechsler Adult Intelligence Scale, Third Edition, Administration and Scoring Manual. San Antonio, TX, The Psychological Corporation, Harcourt Brace & Co, 1997
  76. Weiner DK, Rudy TE, Morrow L, Slaboda J, Lieber S. The relationship between pain, neuropsychological performance, and physical function in community-dwelling older adults with chronic low back pain. Pain Med. 2006;7:60–70
  77. Williamson EM, Evans FJ. Cannabinoids in clinical practice. Drugs. 2000;60:1303–1314

 Supported by grant C01-DA-114 from the University of California Center for Medicinal Cannabis Research.

 Alexander Tsodikov is currently at the School of Public Health, University of Michigan, Ann Arbor, MI.

PII: S1526-5900(08)00369-6

doi: 10.1016/j.jpain.2007.12.010

The Journal of Pain
Volume 9, Issue 6 , Pages 506-521 , June 2008

Article Tools

* Image Usage & Resolution